Acorda Therapeutics Inc.
- ACOR
- NASDAQ
- Consumer Products
- Latest 34.84
- Currency US$
- Change -0.11
- Percent Change -0.315 %
- Volume 291,793
- Wed Jun 19, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 35.06
- Previous Close 34.95
- High 35.36
- Low 34.684
- Bidx0 --
- Askx0 --
- 52-week High -- 40.87
- 52-week Low -- 21.33
- Beta 1.01
- Market Cap 1,403.36M
- EPS 0.56
- P/E 62.21
- Forward P/E 34.495
- PEG 6.26
- Annual Dividend --
- Yield --
News
- New Memoir by Singer/Songwriter Kristie Salerno Kent Follows Her Journey as a Multiple Sclerosis Patient Advocate
- Acorda to Present New Research on AMPYRA® at Fifth Cooperative Meeting of CMSC and ACTRIMS
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
- Acorda Therapeutics' Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
Financials & Calendars
- Sales $306,430,000
- Earnings $145,970,000
- Return on Equity 37.55%
- Cash Flow --
- Cash $34,680,000
- Current Ratio 4.04
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $565,420,000
- Liabilities $173,780,000
- Liabilities-to-Equity Ratio 0.44
Price Ratios
- Price to Sales 4.58
- Price to Book 3.58
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 2 | $0.18 | Aug 6 | $0.10 |
| Surprises | May 2 | -116.67% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended Jun 19, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.
Officers
- Ron Cohen, M.D. Chief Executive Officer & Pres
- David Lawrence, M.B.A. Chief Financial Officer
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
420 SAW MILL RIVER ROADARDSLEY, NY
10502
Phone: (914)-347-4300
Fax: (914)-3474560
Ideas & Discussion
Live Discussion of ACOR on StockTwits